The urinary incontinence and overactive bladder market size is estimated to show notable gains during the foreseeable time frame owing to increasing investments in R&D together with rising government incentives. Multiplying ageing population will further enhance business growth. Technological development related to clinical studies along with favourable health care reforms is supporting in the industry growth rate between 2022 and 2027.
Minimum side effects, site-specific local drug delivery, and combination therapies are few major industry trends. However, declining factors such as lack of awareness, social stigmas associated with disease, shifting trend towards alternative therapies and treatments, and drug patent expirations are expected to negatively impact the industry size.
Global urinary incontinence and overactive bladder market is segmented based on the product as, Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity. Global urinary incontinence and overactive bladder market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional urinary incontinence and overactive bladder market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global urinary incontinence and overactive bladder market share consists of several players including Astellas Pharma Inc., Endo International, Pfizer, Inc., Allergan, PLC., Actavis, Merck & Co., Mylan N.V., Teva Pharmaceutical Industries Limited and Ferring Pharmaceuticals A/S.
The Urinary Incontinence and Overactive Bladder Market has been segmented as below:
Urinary Incontinence and Overactive Bladder Market, By Product
Urinary Incontinence and Overactive Bladder Market, By Region
The report covers:
Report scope:
The global urinary incontinence and overactive bladder market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends.
The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Astellas Pharma Inc., Endo International, Pfizer, Inc., Allergan, PLC., Actavis, Merck & Co., Mylan N.V., Teva Pharmaceutical Industries Limited and Ferring Pharmaceuticals A/S.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Drugs developed for alternative delivery systems
4.2.2. Drug Pipeline
4.3. Restraints
4.3.1. Effect of yoga on urinary incontinence
4.4. Opportunities
4.4.1. New class of treatment for overactive bladders
4.4.2. Merger and acquisition among industry players
4.5. Challenges
4.5.1. Drug patent expirations
5. Urinary Incontinence and Overactive Bladder Market, By Product
5.1. Key Points
5.2. Idiopathic Bladder Overactivity
5.3. Neurogenic Bladder Overactivity
6. Competitive Landscape
6.1. Introduction
6.2. Recent Developments
6.2.1. Mergers & Acquisitions
6.2.2. New Product Developments
6.2.3. Portfolio/Production Capacity Expansions
6.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
6.2.5. Others
7. Company Profile
7.1. Astellas Pharma Inc.
7.1.1. Company Overview
7.1.2. Product/Service Landscape
7.1.3. Financial Overview
7.1.4. Recent Developments
7.2. Endo International
7.2.1. Company Overview
7.2.2. Product/Service Landscape
7.2.3. Financial Overview
7.2.4. Recent Developments
7.3. Pfizer, Inc.
7.3.1. Company Overview
7.3.2. Product/Service Landscape
7.3.3. Financial Overview
7.3.4. Recent Developments
7.4. Allergan, PLC.
7.4.1. Company Overview
7.4.2. Product/Service Landscape
7.4.3. Financial Overview
7.4.4. Recent Developments
7.5. Actavis
7.5.1. Company Overview
7.5.2. Product/Service Landscape
7.5.3. Financial Overview
7.5.4. Recent Developments
7.6. Merck & Co.
7.6.1. Company Overview
7.6.2. Product/Service Landscape
7.6.3. Financial Overview
7.6.4. Recent Developments
7.7. Mylan N.V.
7.7.1. Company Overview
7.7.2. Product/Service Landscape
7.7.3. Financial Overview
7.7.4. Recent Developments
7.8. Teva Pharmaceutical Industries Limited
7.8.1. Company Overview
7.8.2. Product/Service Landscape
7.8.3. Financial Overview
7.8.4. Recent Developments
7.9. Ferring Pharmaceuticals A/S
7.9.1. Company Overview
7.9.2. Product/Service Landscape
7.9.3. Financial Overview
7.9.4. Recent Developments
The Urinary Incontinence and Overactive Bladder Market has been segmented as below:
Urinary Incontinence and Overactive Bladder Market, By Product
Urinary Incontinence and Overactive Bladder Market, By Region
